Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.

Current Medical Research and Opinion, 2016 32(5): 817-827. e-pub ahead of print 2016/01/09

Though the median age at diagnosis is 64 years, few studies focus on elderly (≥65 years) patients with chronic myeloid leukemia (CML). This study examines healthcare outcomes among elderly Medicare beneficiaries with CML who started nilotinib or dasatinib after imatinib. 

View abstract


Smith BD, Liu J, Latremouille-Viau D, Guerin A, Fernandez D, Chen L.